Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Condensed Consolidated Statements of Operations and Comprehensive Loss
Grant revenue	$ 1,848	$ 354,621	$ 282,422	$ 1,296,764
Operating expenses:
Research and development	1,638,917	2,846,399	6,034,196	7,004,451
General and administrative	1,480,319	1,605,238	4,838,969	5,385,923
Total operating expenses	3,119,236	4,451,637	10,873,165	12,390,374
Loss from operations	(3,117,388)	(4,097,016)	(10,590,743)	(11,093,610)
Other income (expense):
Interest income, net	150,669	348,741	533,422	1,014,518
Foreign currency (loss) gain	(5,691)	(35,494)	(86,618)	15,180
Total other income	144,978	313,247	446,804	1,029,698
Net loss	(2,972,410)	(3,783,769)	(10,143,939)	(10,063,912)
Other comprehensive (loss) income:
Foreign currency translation	(1,117)	23,557	(2,155)	6,526
Total comprehensive loss	$ (2,973,527)	$ (3,760,212)	$ (10,146,094)	$ (10,057,386)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.47)	$ (0.64)	$ (1.65)	$ (1.88)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.47)	$ (0.64)	$ (1.65)	$ (1.88)
Weighted-average common shares outstanding, basic (in shares)	6,372,938	5,939,755	6,151,433	5,360,579
Weighted-average common shares outstanding, diluted (in shares)	6,372,938	5,939,755	6,151,433	5,360,579